Overview


According to FutureWise analysis the market for antiplatelet drugs in 2023 is US$ 2.41 billion, and is expected to reach US$ 4.56 billion by 2031 at a CAGR of 8.30%.

Antiplatelet medications are categorized into oral and parenteral agents, with further subdivisions based on their mechanisms of action. Oral antiplatelet drugs encompass aspirin, a cyclooxygenase inhibitor, clopidogrel, ticagrelor, prasugrel, Cilostazol, and dipyridamole. Parenteral glycoprotein IIb/IIIa inhibitors like tirofiban and eptifibatide are exclusively used in acute phases of acute coronary syndrome.

These medications serve a multitude of clinical indications, including acute coronary syndrome, post-percutaneous coronary intervention with stenting, and acute ischemic stroke, among others. Mechanistically, antiplatelets operate through various pathways. Aspirin, the most widely used oral antiplatelet, irreversibly inhibits cyclooxygenase enzyme activity, disrupting prostaglandin synthesis and ultimately impeding platelet aggregation. Oral thienopyridines, including clopidogrel, ticagrelor, ticlopidine, and prasugrel, selectively hinder adenosine diphosphate-induced platelet aggregation. Glycoprotein platelet inhibitors act by inhibiting glycoprotein IIb/IIIa receptors on platelets, leading to decreased aggregation, primarily employed in acute coronary syndrome scenarios. Dipyridamole exerts its effects by inhibiting platelet cyclic nucleotide phosphodiesterase, preventing platelet aggregation, and promoting vasodilation. On the other hand, Cilostazol exhibits vasodilatory, antiplatelet, and antiproliferative attributes, mitigating smooth muscle cell overgrowth and intimal thickening following endothelial injury. The mode of administration varies, encompassing oral, rectal, or intravenous routes, contingent upon the particular medication in question.

FutureWise Market Research has published a report that provides an insightful analysis of Antiplatelet Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antiplatelet Drugs Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • The Medicines Company
  • AstraZeneca
  • Portola Pharmaceuticals, Inc.
  • Bayer Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Altimed Pharma Inc.
  • Dominion Pharmacal
  • Alta Laboratories Ltd
  • Novacap
  • Shandong Xinhua Pharmaceutical
  • Nanjing Pharmaceutical Factory
  • Sanis Health Inc
  • Syntex Inc.
  • Hoffmann La Roche
  • Teva
  • Sandoz Canada Incorporated
  • Pharmascience Inc
  • Nu Pharm Inc
  • Mylan Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antiplatelet Drugs Market:

  • In June 2021, Alfasigma revealed that it had secured European licensing approval for bentracimab, a groundbreaking human monoclonal antibody fragment obtained from PhaseBio. Extensive clinical trials have demonstrated bentracimab's effectiveness in reversing the antiplatelet effects of Brilinta / Brilique. 

More people worldwide are getting heart-related problems, which is a big reason why the market for antiplatelet drugs is growing. This is because of a sedentary lifestyle, not eating well, and more older people. These factors make heart problems more common. Antiplatelet drugs are like helpers that stop blood from forming clots, which can cause heart problems. Technology that helps doctors find heart issues early has gotten much better. This means that when they see a problem, they can start treatment quickly, often with these antiplatelet drugs. This makes more people want these drugs, making the market bigger. People are becoming more aware of how important it is to care for their health before they get sick. They know these drugs can help prevent heart attacks and strokes. Because of this, more people are taking these drugs regularly, and there is a higher demand for them. There are better hospitals in places where the economy is growing, and more people can see a doctor. This means that more people can get these antiplatelet drugs. In these places, more people are moving up to the middle class and learning more about how to take care of their hearts. This makes the market for these drugs grow even more.

One of the most significant restraints for antiplatelet drugs is the inherent risk of bleeding, ranging from mild to severe. Balancing the need for effective platelet inhibition with the potential for hemorrhagic complications is a complex clinical decision. Physicians must carefully assess each patient's risk profile and monitor them closely during treatment. The availability of alternative interventions, such as anticoagulants and interventional procedures, presents a competitive challenge for the antiplatelet drugs market.

By Drug Type

  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Dipyridamole
  • Ticlopidine
  • Abciximab
  • Tirofiban
  • Others

By Application

  • Myocardial Infraction
  • Percutaneous Coronary Interventions
  • Angioplasty
  • Arterial Thrombosis
  • Dental surgeries
  • Others

By End User

  • Hospitals
  • Clinic
  • Emergency Service Centers
  • Ambulatory surgical centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the growing adoption of newer technologies and increasing demand for diseases-specific treatment. Additionally, the presence of key players is rising, and healthcare expenditure is also rising. This propels the market in this region. Europe is expected to grow due to the surging myocardial infection cases and an escalating demand for high-quality healthcare services.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antiplatelet Drugs Market By Drug Type, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antiplatelet Drugs Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antiplatelet Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antiplatelet Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antiplatelet Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Aspirin
        2. Clopidogrel
        3. Ticagrelor
        4. Prasugrel
        5. Dipyridamole
        6. Ticlopidine
        7. Abciximab
        8. Tirofiban
        9. Others

  • 8.   Global Antiplatelet Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Myocardial Infraction
        2. Percutaneous Coronary Interventions
        3. Angioplasty
        4. Arterial Thrombosis
        5. Dental surgeries
        6. Others

  • 9.   Global Antiplatelet Drugs Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinic
        3. Emergency Service Centers
        4. Ambulatory surgical centers
        5. Others

  • 10.   North America Antiplatelet Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antiplatelet Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antiplatelet Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antiplatelet Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. The Medicines Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AstraZeneca
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Portola Pharmaceuticals, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer Pharmaceuticals
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bristol-Myers Squibb Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Boehringer Ingelheim Pharmaceuticals, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Altimed Pharma Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Dominion Pharmacal
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Alta Laboratories Ltd
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Novacap
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Shandong Xinhua Pharmaceutical
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Nanjing Pharmaceutical Factory
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Sanis Health Inc
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Syntex Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Hoffmann La Roche
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Teva
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Sandoz Canada Incorporated
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Pharmascience Inc
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Nu Pharm Inc
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Mylan Pharmaceuticals
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Antiplatelet Market

Read More

Oral Antiplatelets Market

Read More
Partner

Our Clients